Dna Group (T.R.) Ltd (DNA.TA)
- Previous Close
103.10 - Open
105.10 - Bid 102.30 x 541600
- Ask 104.50 x 566500
- Day's Range
102.00 - 109.70 - 52 Week Range
59.00 - 118.90 - Volume
64,585 - Avg. Volume
115,736 - Market Cap (intraday)
130.579M - Beta (5Y Monthly) -0.13
- PE Ratio (TTM)
5.81 - EPS (TTM)
0.18 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.
Recent News: DNA.TA
View More
Performance Overview: DNA.TA
Trailing total returns as of 4/27/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNA.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNA.TA
View MoreValuation Measures
Market Cap
126.98M
Enterprise Value
58.67M
Trailing P/E
5.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
415.08
Price/Book (mrq)
1.25
Enterprise Value/Revenue
191.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
7,220.92%
Return on Assets (ttm)
-1.02%
Return on Equity (ttm)
24.46%
Revenue (ttm)
306k
Net Income Avi to Common (ttm)
22.1M
Diluted EPS (ttm)
0.18
Balance Sheet and Cash Flow
Total Cash (mrq)
68.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-205.75k